Page 21 - Journal of Structural Heart Disease Volume 3, Issue 2

47 Case Report
Figure 6. Medications and examinations after ASO implantation. 6MD = 6-min walk distance; ASO = Amplatzer septal occluder; m = mean; PA = pulmonary artery; PCW = pulmonary capillary wedge; RA = right atrium; s/d/m = systolic/diastolic/mean.
presence of chronic massive pericardial e usion, the reduction in pulmonary arterial pressure fell short of our expectations. Because pericardiocentesis had no e ect on pericardial e usion, pericardiostomy and drainage was performed according to previous re- ports [9]. Finally, the surgical procedure eliminated the e usion, which was followed by a decrease in pul- monary artery pressure to a nearly normal level and the disappearance of symptoms.
Conclusions
We report a case of giant ASD with massive pericar- dial e usion treated by ASO followed by the adminis- tration of pulmonary arterial dilators. Potent pulmo- nary hypertension drugs and percutaneous closure devices make high-risk ASD treatment possible, even in elderly and frail patients.
Con ict of Interest
The authors have no con ict of interest relevant to this publication.
Comment on this Article or Ask a Question
Figure 7.
Short-axis view of transthoracic echocardiography after drainage of the pericardial e usion 6 months after atrial septal defect closure. The left ventricular shape became round, and the dimension of the left ventricle increased.
sure was greater than 70% of systemic pressure [8]. The pulmonary hypertension-speci c medications that we administered are reportedly e ective even in high-risk patients during long-term follow-up [8]. However, in our particular case, probably due to the
Kikuchi, N. et al.
Percutaneous Device Closure for Giant ASD and PE